SCHEMBL5992019

SCHEMBL5992019

CCc1ccc(Nc2c(C(=O)NOC(CO)CO)ccc(F)c2F)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 17/20 0.54
MAP2K2 P36507 7/20 0.54
MAPK1 P28482 2/20 0.54
BRAF P15056 1/20 0.54
MAP2K5 Q13163 1/20 0.54
PIM1 P11309 1/20 0.50
CAMK2B Q13554 1/20 0.50
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4853570 0.85 MAP2K1 (0.73) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5990209 0.85 MAP2K1 (0.75) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5990204 0.85 MAP2K1 (0.75) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5990207 0.85 MAP2K1 (0.75) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL6187974 0.84 MAP2K1 (0.53) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5989889 0.84 MAP2K1 (0.75) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL4860706 0.84 MAP2K1 (0.68) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5990333 0.82 MAP2K1 (0.54) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL6319695 0.80 MAP2K1 (0.50) MAP2K1MAP2K2MAPK1BRAFMAP2K5
SCHEMBL5989634 0.80 MAP2K1 (0.66) MAP2K1MAP2K2PIM1CAMK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6891066-B2 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2005-05-10 US claimed
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters REWCASTLE GORDON WILLIAM (NZ) 2004-01-08 US claimed
US-7078438-B2 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2006-07-18 US disclosed
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY, LLC 2005-06-23 US disclosed
US-6891066-B2 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2005-05-10 US disclosed
EP-1467968-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS Warner-Lambert Company LLC (US) 2004-10-20 EP disclosed
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters REWCASTLE GORDON WILLIAM (NZ) 2004-01-08 US disclosed
WO-2003062191-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters PAH, EGLN3, PAOX MAP2K1 4555/4885MAP2K2 4495/4885MAPK1 4754/4885
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters HCAR2, EGLN3, AADAC MAP2K1 4692/4885MAP2K2 4611/4885MAPK1 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.